Oral Colorectal Presentations: Discussion Abstracts #4009 - #4011 Cathy Eng, M.D. The University of Texas M.D. Anderson Cancer Center May 31, 2008.
Www.OncologyEducation.ca KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI.
MOSAIC
MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.
A Report from ASCO 2007 First-Line Metastatic Colorectal Cancer
![MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.](https://static.fdocuments.net/doc/330x215/56649cac5503460f9496e2a1/mosaic-stage-lllll-folfox4-lv5fu2-randomize-dfs-dfs-months-hazard-ratio.jpg)
